MIDATECH PHARMA PLC-ADR (MTP)

US59564R5000 - ADR

0.2851  -0.06 (-18.52%)

After market: 0.2801 -0.01 (-1.75%)

Fundamental Rating

1

MTP gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 592 industry peers in the Biotechnology industry. MTP has a bad profitability rating. Also its financial health evaluation is rather negative. MTP does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

MTP had negative earnings in the past year.
MTP had a negative operating cash flow in the past year.
In the past 5 years MTP always reported negative net income.
MTP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MTP has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MTP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

MTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MTP has been increased compared to 1 year ago.
Compared to 1 year ago, MTP has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -12.33, we must say that MTP is in the distress zone and has some risk of bankruptcy.
MTP's Altman-Z score of -12.33 is on the low side compared to the rest of the industry. MTP is outperformed by 81.14% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MTP is not too dependend on debt financing.
MTP's Debt to Equity ratio of 0.07 is on the low side compared to the rest of the industry. MTP is outperformed by 62.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -12.33
ROIC/WACCN/A
WACC6.79%

2.3 Liquidity

A Current Ratio of 5.28 indicates that MTP has no problem at all paying its short term obligations.
MTP's Current ratio of 5.28 is in line compared to the rest of the industry. MTP outperforms 47.70% of its industry peers.
MTP has a Quick Ratio of 5.28. This indicates that MTP is financially healthy and has no problem in meeting its short term obligations.
MTP has a Quick ratio (5.28) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 5.28

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.43% over the past year.
The Revenue has grown by 11.98% in the past year. This is quite good.
MTP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.26% yearly.
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q37.63%
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Revenue growth Q2Q16.71%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTP. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for MTP!.
Industry RankSector Rank
Dividend Yield N/A

MIDATECH PHARMA PLC-ADR

NASDAQ:MTP (3/24/2023, 8:00:00 PM)

After market: 0.2801 -0.01 (-1.75%)

0.2851

-0.06 (-18.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.98M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.28
Quick Ratio 5.28
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y